Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy

South African Medical Journal

Volumn 97, Issue 12 I, 2007, Pages 1255-1257

  Schapkaitz, Elise ^a   Jacobson, Barry F ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CLOMIFENE CITRATE; CORTISONE; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CESAREAN SECTION; CLINICAL PROTOCOL; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GESTATION PERIOD; HUMAN; INJECTION SITE REACTION; LUNG EMBOLISM; PRURITUS; PUERPERIUM; RECURRENT DISEASE; SKIN MANIFESTATION; TREATMENT OUTCOME; TWIN PREGNANCY;

ADULT; ANTICOAGULANTS; CORTISONE; DRUG ERUPTIONS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; NADROPARIN; OINTMENTS; POLYSACCHARIDES; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PULMONARY EMBOLISM;

EID: 38549099897     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3): Suppl, 627S-644S.
2. Ginsberg JS, Chan WS, Bates SM, Katz S. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2003; 163(6): 694-698.
3. Monreal M, Lafoz E, Olive A, dei Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71(1): 7-11.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3): Suppl, 311S-337S.
5. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127(5): 1857-1861.
6. Phillips JK, Majumdar G, Hunt BJ, Savidge GE Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH). Br J Haematol 1993; 84(2): 349-350.
7. Sanson BJ, Lensing AW, Prins MH, etal. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-672.
8. Baglin TP. Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis. Haemostasis 1996; 26: Suppl 2, 10-15.
9. Bircher AJ, Itin PH, Tsakiris DA, Surber C. Delayed hypersensitivity to one low-molecular-weight heparin with tolerance of other low-molecular-weight heparins. Br J Dermatol 1995; 132(3): 461-463.
10. Mora A, Belchi J, Contreras L, Rubio G. Delayed-type hypersensitivity skin reactions to low molecular weight heparins in a pregnant woman. Contact Dermatitis 2002; 47(3): 177-178.
11. Samama MM, Gerotziafas GT. Evaluation of the pharmacologicaI properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109(1): 1-11.
12. Bank I, Libottrel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003; 1(4): 859-861.
13. Tonn ME, Schaiff RA, KΦllef MH. Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. Ann Pharmacother 1997; 31(3): 323-326.
14. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92(2): 494-497.
15. lturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-1393.
16. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001; 67(4): 268-269.
17. Harrison SJ, Rafferty I, McColl MD. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 2001; 12(2): 157-159.
18. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93(1): 63-69.
19. Myers B, Westby J, Strong I. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis 2003; 14(5): 485-487.
20. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
21. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345(18): 1298-304.
22. Sacher C, Hunzelmann N. Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitizafion. Allergy 2003; 58(12): 1318-1319.
23. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. ToIerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2003; 49(6): 276-280.
24. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or infractionated heparin. 0N Engl J Med 1995; 332(20): 1330-1335.
25. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96(3): 274-284.
26. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350(18): 1914-1915.